Bridgefront Capital LLC Makes New $562,000 Investment in Repligen Co. (NASDAQ:RGEN)

Bridgefront Capital LLC acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,904 shares of the biotechnology company's stock, valued at approximately $562,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Signaturefd LLC grew its position in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new stake in shares of Repligen in the 4th quarter valued at approximately $29,000. Itau Unibanco Holding S.A. purchased a new position in shares of Repligen in the 4th quarter worth approximately $40,000. UMB Bank n.a. raised its holdings in Repligen by 49.1% during the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after buying an additional 110 shares during the period. Finally, Global Retirement Partners LLC lifted its position in Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after buying an additional 129 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Down 3.6 %

NASDAQ RGEN traded down $4.61 during midday trading on Friday, hitting $123.24. 580,989 shares of the company traded hands, compared to its average volume of 727,651. The company has a market cap of $6.92 billion, a PE ratio of -241.65, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company's 50-day simple moving average is $135.03 and its 200-day simple moving average is $145.37. Repligen Co. has a 52 week low of $102.97 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Repligen's revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.28 EPS. As a group, equities research analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on RGEN. Canaccord Genuity Group cut their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. TD Cowen began coverage on Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. Royal Bank of Canada reduced their price target on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. JPMorgan Chase & Co. dropped their price objective on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Finally, Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research note on Tuesday, April 29th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $173.25.

Insider Buying and Selling

In related news, Director Margaret Pax acquired 250 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.